GO:0047179 platelet-activating factor acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047179 describes the enzymatic activity that transfers an acetyl group from 1-radyl-2-acyl-sn-glycero-3-phospholipid to 1-alkyl-2-lyso-sn-glycero-3-phosphocholine, producing platelet-activating factor (PAF) and a lysophospholipid.
• This acetyltransferase is a key enzyme in the remodeling pathway of PAF biosynthesis, which is activated in inflammatory cells such as neutrophils and endothelial cells.
• PAF acetyltransferase activity is elevated in inflammatory and cardiovascular conditions, including asthma, heart failure, and coronary heart disease.
• The enzyme is stimulated by PAF itself, creating a positive feedback loop that amplifies PAF production during inflammation.
• Specific inhibitors such as ZG-1494 alpha have been isolated and used to study the enzyme's role in PAF-mediated signaling.
• Studying GO:0047179 requires integrating enzyme activity assays, lipidomics, and CRISPR-based genetic models to dissect its contribution to disease.
Description
Platelet-activating factor acetyltransferase activity (GO:0047179) is a molecular function that catalyzes the transfer of an acetyl group from a 1-radyl-2-acyl-sn-glycero-3-phospholipid to 1-alkyl-2-lyso-sn-glycero-3-phosphocholine, yielding platelet-activating factor (PAF) and a lysophospholipid. This reaction constitutes the final step of the remodeling pathway for PAF biosynthesis, a route that is rapidly activated in response to inflammatory stimuli. PAF is a potent phospholipid mediator involved in diverse physiological and pathological processes, including leukocyte activation, vascular permeability, and thrombosis. Consequently, the enzyme responsible for its production has attracted considerable interest as a therapeutic target in inflammatory and cardiovascular diseases. Researchers study GO:0047179 to understand how PAF is generated in specific cell types and how this production is dysregulated in disease. For example, neutrophils from asthmatic patients display altered acetyltransferase activity compared to normal subjects, and patients with heart failure show changes in the activity of PAF biosynthetic enzymes. The enzyme is also expressed in glomerular endothelial cells, where it contributes to local PAF synthesis. These findings highlight the importance of this activity in both acute and chronic inflammatory settings. This article provides a research-grade overview of GO:0047179, covering its definition, mechanism, key genes, regulation, disease associations, and experimental methods. By integrating authoritative QuickGO data with verified PubMed literature, we aim to support researchers in designing robust studies on PAF acetyltransferase and its role in health and disease.
platelet-activating factor acetyltransferase activity At A Glance
| GO ID | GO:0047179 |
|---|---|
| GO term | platelet-activating factor acetyltransferase activity |
| Ontology | molecular_function |
| Synonym | PAF acetyltransferase activity; 1-alkyl-2-acyl-sn-glycero-3-phosphocholine:1-organyl-2-lyso-sn-glycero-3-phospholipid acetyltransferase activity |
| Major function | Catalyzes the final step in the remodeling pathway of PAF biosynthesis |
| Reaction | 1-radyl-2-acyl-sn-glycero-3-phospholipid + 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine = 1-alkyl-2-lyso-sn-glycero-3-phosphocholine + 1-radyl-2-acetyl-sn-glycero-3-phospholipid |
| Substrates | 1-radyl-2-acyl-sn-glycero-3-phospholipid (acetyl donor); 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (acceptor) |
| Products | 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF); 1-radyl-2-lyso-sn-glycero-3-phospholipid |
| Cellular context | Cytosol and membranes of inflammatory cells, endothelial cells, and leukocytes |
What Is GO:0047179?
GO:0047179, platelet-activating factor acetyltransferase activity, is defined as the catalysis of the reaction: 1-radyl-2-acyl-sn-glycero-3-phospholipid + 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine = 1-alkyl-2-lyso-sn-glycero-3-phosphocholine + 1-radyl-2-acetyl-sn-glycero-3-phospholipid. In simpler terms, this enzyme moves an acetyl group from one phospholipid to another, converting a lysophospholipid precursor into platelet-activating factor (PAF) while generating a lysophospholipid byproduct. This activity is synonymous with PAF acetyltransferase activity and 1-alkyl-2-acyl-sn-glycero-3-phosphocholine:1-organyl-2-lyso-sn-glycero-3-phospholipid acetyltransferase activity.
Why Is platelet-activating factor acetyltransferase activity Important in Cell Biology?
GO:0047179 is critical because it governs the production of platelet-activating factor (PAF), a phospholipid mediator with potent pro-inflammatory and thrombotic activities. Dysregulated PAF acetyltransferase activity has been implicated in asthma, heart failure, and coronary heart disease, making it a potential biomarker and therapeutic target. Understanding this activity at the molecular level can inform the development of inhibitors or modulators for clinical use.
• PAF acetyltransferase activity is the rate-limiting step in the remodeling pathway of PAF synthesis, controlling the availability of this potent mediator.
• Elevated enzyme activity has been observed in neutrophils from asthmatic patients, linking it to allergic inflammation.
• The activity is modulated in patients with heart failure, suggesting a role in cardiovascular pathology.
• Moderate wine consumption affects PAF-metabolizing enzymes, including acetyltransferase, in men with coronary heart disease.
• PAF stimulates its own synthesis by activating the acetyltransferase, creating a positive feedback loop.
• The enzyme is expressed in glomerular endothelial cells, where it may contribute to renal inflammation.
• Specific inhibitors like ZG-1494 alpha provide tools to probe the enzyme's function and therapeutic potential.
• Assessing acetyltransferase activity in leukocytes can serve as a readout for inflammatory status.
• The enzyme's activity can be measured using acetyl-CoA-dependent assays, facilitating high-throughput screening.
• Genetic and pharmacological manipulation of this activity may help dissect its role in thrombosis and atherosclerosis.
Mechanism, Genes and Research Methods
Substrate Recognition and Binding
In simple terms: The enzyme grabs two lipid molecules and prepares to move an acetyl group between them.
The acetyltransferase binds two substrates: a 1-radyl-2-acyl-sn-glycero-3-phospholipid (acetyl donor) and 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (acceptor). The enzyme likely recognizes the sn-1 alkyl/radyl and sn-2 acyl/lyso groups to position the substrates for catalysis. This binding step is essential for the subsequent acetyl transfer and is influenced by the lipid composition of the membrane environment.
Catalytic Transfer of the Acetyl Group
In simple terms: The enzyme moves the acetyl group from one lipid to the other, creating PAF.
Following substrate binding, the enzyme catalyzes the transfer of the acetyl group from the donor phospholipid to the acceptor lysophospholipid, yielding PAF and a lysophospholipid byproduct. This reaction is reversible in vitro, but in cells it is driven toward PAF synthesis by the availability of substrates and the rapid metabolism of PAF. The catalytic mechanism likely involves a conserved histidine or serine residue acting as a nucleophile, although the exact residues remain to be fully defined.
Regulation by PAF and Inflammatory Mediators
In simple terms: PAF itself can boost the enzyme's activity, leading to more PAF production.
PAF stimulates the acetyltransferase activity in neutrophils and leukocyte-rich plasma, establishing a positive feedback loop that amplifies PAF synthesis during inflammation. This stimulation may involve phosphorylation events or changes in substrate availability, but the precise signaling pathways are still under investigation. Other inflammatory mediators, such as cytokines and chemokines, may also modulate enzyme activity indirectly.
Inhibition and Pharmacological Modulation
In simple terms: Certain chemicals can block the enzyme, reducing PAF production.
Specific inhibitors of PAF acetyltransferase, such as ZG-1494 alpha isolated from Penicillium rubrum, have been identified and shown to inhibit the enzyme's activity. These inhibitors are valuable tools for studying the enzyme's role in PAF-mediated processes and for developing potential therapeutics. Additionally, PAF antagonists can indirectly affect the enzyme by blocking PAF's stimulatory feedback.
Key Genes Involved in GO:0047179 platelet-activating factor acetyltransferase activity
The following genes and proteins are directly or indirectly associated with platelet-activating factor acetyltransferase activity (GO:0047179), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPCAT1 | Lysophosphatidylcholine acyltransferase 1; may exhibit PAF acetyltransferase activity | Potential candidate for the enzyme; studied in lipid metabolism |
| LPCAT2 | Lysophosphatidylcholine acyltransferase 2; known to possess PAF acetyltransferase activity | Directly catalyzes PAF synthesis in inflammatory cells |
| PLA2G7 | Lipoprotein-associated phospholipase A2; degrades PAF | Regulates PAF levels and indirectly affects acetyltransferase demand |
| PAFAH1B1 | PAF acetylhydrolase 1b, alpha subunit; catabolizes PAF | Balances PAF levels; mutations linked to brain development |
| PAFAH1B2 | PAF acetylhydrolase 1b, beta subunit; catabolizes PAF | Contributes to PAF degradation |
| PAFAH1B3 | PAF acetylhydrolase 1b, gamma subunit; catabolizes PAF | Part of the PAF degradation machinery |
| PAFAH2 | PAF acetylhydrolase 2; plasma form | Regulates systemic PAF levels |
| CHAT | Choline acetyltransferase; unrelated but shares acetyltransferase name | Not directly involved; caution in literature searches |
| LYPLA1 | Lysophospholipase 1; may influence lysophospholipid substrates | Indirect role in substrate supply |
| LYPLA2 | Lysophospholipase 2; may influence lysophospholipid substrates | Indirect role in substrate supply |
| PLA2G4A | Cytosolic phospholipase A2; releases arachidonic acid and lysophospholipids | Provides substrates for PAF synthesis |
| PLA2G4B | Cytosolic phospholipase A2 beta | May modulate lipid mediator production |
| PLA2G4C | Cytosolic phospholipase A2 gamma | Potential role in phospholipid remodeling |
| PLA2G4D | Cytosolic phospholipase A2 delta | Potential role in phospholipid remodeling |
| PLA2G4E | Cytosolic phospholipase A2 epsilon | Potential role in phospholipid remodeling |
| PLA2G4F | Cytosolic phospholipase A2 zeta | Potential role in phospholipid remodeling |
| PLA2G10 | Secretory phospholipase A2 group X | May influence substrate availability |
| PLA2G2A | Secretory phospholipase A2 group IIA | Involved in inflammatory lipid mediator production |
How Is platelet-activating factor acetyltransferase activity Regulated?
The activity of platelet-activating factor acetyltransferase is regulated at multiple levels. PAF itself stimulates the enzyme, creating a positive feedback loop that enhances PAF production during inflammation. Inflammatory mediators and cytokines may also modulate enzyme activity, as suggested by altered activity in heart failure and asthma. Additionally, the availability of substrates, such as lysophospholipids and acetyl-CoA donors, can influence the reaction rate. Pharmacological inhibition by compounds like ZG-1494 alpha provides a means to downregulate activity.
platelet-activating factor acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPCAT2 | Inflammatory diseases (asthma, sepsis) | Knockout mice or cell lines to assess PAF production |
| PLA2G7 | Cardiovascular disease | Overexpression or knockout in endothelial cells |
| PAFAH1B1 | Neurodevelopmental disorders | Point mutation knock-in to mimic human mutations |
| LPCAT1 | Cancer and inflammation | CRISPR knockout in cancer cell lines |
| PLA2G4A | Inflammatory bowel disease | Conditional knockout in intestinal epithelium |
Asthma and Allergic Inflammation
Neutrophils from asthmatic patients exhibit altered acetyl-CoA:lyso-PAF acetyltransferase activity compared to normal subjects, suggesting a role for this enzyme in asthma pathogenesis. The enzyme's product, PAF, is a potent bronchoconstrictor and chemoattractant, contributing to airway inflammation.
Heart Failure and Cardiovascular Disease
Patients with newly diagnosed heart failure show changes in the activity of PAF biosynthetic enzymes, including acetyltransferase, in blood and leukocytes. Moderate wine consumption has been shown to affect PAF-metabolizing enzymes in men with coronary heart disease, indicating a link between diet, enzyme activity, and cardiovascular risk.
Renal Inflammation
Glomerular endothelial cells express PAF acetyltransferase activity, and its synthesis of PAF may contribute to glomerular inflammation and injury. This suggests a potential role in kidney diseases characterized by endothelial activation.
From platelet-activating factor acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LPCAT2 reduce PAF production? | LPCAT2 knockout cell line (e.g., HEK293 or neutrophils) |
| Does a specific point mutation in LPCAT2 abolish acetyltransferase activity? | Point mutation knock-in via CRISPR in cell lines |
| Can tagged LPCAT2 be used to track subcellular localization? | Knock-in of FLAG or GFP tag at endogenous locus |
| Does overexpression of LPCAT2 increase PAF levels? | Stable overexpression in endothelial cells |
| Which genes regulate PAF acetyltransferase activity? | CRISPR library screening in inflammatory cells |
| Does pharmacological inhibition of PAF acetyltransferase reduce inflammation? | Inhibitor treatment in wild-type and knockout models |
How to Study the platelet-activating factor acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acetyltransferase activity assay | Enzyme activity using radiolabeled or fluorescent substrates | Kinetic studies, inhibitor screening |
| Mass spectrometry lipidomics | Levels of PAF and related phospholipids | Quantification in cells and tissues |
| CRISPR knockout | Loss-of-function effects on PAF production | Target validation in cell lines |
| CRISPR point mutation | Effect of specific amino acid changes on enzyme activity | Structure-function studies |
| RNA-seq | Transcriptional changes in PAF pathway genes | Disease profiling and drug response |
| Proteomics | Protein abundance and post-translational modifications | Pathway analysis |
| Immunofluorescence | Subcellular localization of enzyme | Cell biology studies |
| Inhibitor treatment | Pharmacological modulation of enzyme activity | Preclinical therapeutic testing |
Enzyme Activity Assays
Acetyltransferase activity is typically measured using radiolabeled acetyl-CoA or fluorescent substrates, quantifying the formation of PAF or the transfer of acetyl groups. These assays can be performed on cell lysates or purified enzyme preparations and are suitable for kinetic studies and inhibitor screening.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics allows direct quantification of PAF and related phospholipids in biological samples, providing a comprehensive view of the enzyme's impact on lipid mediator networks. This approach is valuable for validating enzyme activity in complex biological matrices.
CRISPR-Cas9 Genetic Models
CRISPR-Cas9 can be used to generate knockout, point mutation, or knock-in cell lines to study the function of genes encoding PAF acetyltransferase or related enzymes. These models enable causal inference and are complementary to pharmacological approaches.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance of PAF-metabolizing enzymes under different conditions, such as inflammation or drug treatment. Integrating these data with enzyme activity measurements provides a systems-level understanding.
How CRISPR Can Be Used to Study GO:0047179 platelet-activating factor acetyltransferase activity
Knockout
CRISPR knockout of genes encoding PAF acetyltransferase (e.g., LPCAT2) can abolish enzyme activity, providing a clean genetic model to study its role in PAF production and inflammation. Knockout cell lines are valuable for validating inhibitor specificity and for identifying compensatory pathways.
Point Mutation
Introducing point mutations in the catalytic domain of PAF acetyltransferase via CRISPR can help identify essential residues for acetyl transfer and substrate binding. Such models are useful for dissecting structure-function relationships and for mimicking human polymorphisms.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous locus allows tracking of enzyme expression, localization, and interactions in live cells. This approach preserves native regulation and is ideal for imaging studies.
Overexpression
CRISPR-mediated overexpression (e.g., via CRISPRa) or lentiviral overexpression of PAF acetyltransferase can increase PAF production, enabling gain-of-function studies in inflammatory and cardiovascular models. Overexpression systems are also useful for producing recombinant enzyme for biochemical assays.
How EDITGENE Supports platelet-activating factor acetyltransferase activity Research
Researchers studying platelet-activating factor acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in PAF production, inflammatory signaling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for platelet-activating factor acetyltransferase activity research.
Frequently Asked Questions About platelet-activating factor acetyltransferase activity
What is platelet-activating factor acetyltransferase activity?
It is the enzymatic activity (GO:0047179) that transfers an acetyl group to a lysophospholipid to produce platelet-activating factor (PAF), a potent inflammatory mediator.
What genes are involved in platelet-activating factor acetyltransferase activity?
Genes such as LPCAT2 and LPCAT1 encode enzymes with this activity, while PLA2G7 and PAFAH1B1 regulate PAF levels.
How is platelet-activating factor acetyltransferase activity measured?
It is typically measured using acetyl-CoA-dependent assays with radiolabeled or fluorescent substrates, often combined with mass spectrometry for lipid quantification.
What diseases are associated with platelet-activating factor acetyltransferase activity?
Asthma, heart failure, and cardiovascular disease have been linked to altered enzyme activity.
Can CRISPR be used to study platelet-activating factor acetyltransferase activity?
Yes, CRISPR knockout, point mutation, and knock-in models can be used to dissect the function of genes encoding this activity.
What is the role of PAF acetyltransferase in inflammation?
It produces PAF, which amplifies inflammation by activating leukocytes and increasing vascular permeability.
Are there inhibitors of platelet-activating factor acetyltransferase?
Yes, ZG-1494 alpha is a natural inhibitor isolated from Penicillium rubrum.
How does PAF regulate its own synthesis?
PAF stimulates the acetyltransferase activity, creating a positive feedback loop that enhances PAF production.
What cell types express platelet-activating factor acetyltransferase?
It is expressed in neutrophils, leukocytes, and glomerular endothelial cells, among others.
What is the difference between PAF acetyltransferase and PAF acetylhydrolase?
PAF acetyltransferase synthesizes PAF, while PAF acetylhydrolase degrades it, maintaining a balance.
Conclusion
Platelet-activating factor acetyltransferase activity (GO:0047179) is a central enzymatic function in the biosynthesis of PAF, a key mediator of inflammation and thrombosis. Its dysregulation is associated with asthma, heart failure, and cardiovascular disease, making it an attractive target for therapeutic intervention. Understanding its mechanism, regulation, and genetic control requires a combination of biochemical, lipidomic, and CRISPR-based approaches. EDITGENE provides the tools and expertise to accelerate research on this activity, from custom CRISPR models to advanced bioinformatics. By leveraging these resources, researchers can uncover new insights into PAF biology and develop novel strategies to modulate inflammatory diseases.
References
- 1. Misso NL et al.. 1993. Acetyl-CoA:lyso-platelet-activating factor acetyltransferase activity in neutrophils from asthmatic patients and normal subjects.. Clin Sci (Lond) 85(4):455-63 PMID: 8222512
- 2. Fragopoulou E et al.. 2025. Effect of moderate wine consumption on the activity of enzymes involved in platelet-activating factor metabolism and thrombotic biomarkers: a randomised, single-blind, parallel, clinical study in CHD men patients.. Br J Nutr 133(5):600-610 PMID: 39939614
- 3. Doebber TW et al.. 1987. Platelet-activating factor (PAF) stimulates the PAF-synthesizing enzyme acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase and PAF synthesis in neutrophils.. Proc Natl Acad Sci U S A 84(21):7557-61 PMID: 3478712
- 4. Detopoulou P et al.. 2009. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure.. Clin Biochem 42(1-2):44-9 PMID: 18955040
- 5. Kester M et al.. 1994. Characterization of platelet-activating factor synthesis in glomerular endothelial cell lines.. Kidney Int 46(5):1404-12 PMID: 7853801
- 6. Doebber TW et al.. 1991. Platelet-activating factor (PAF) stimulates the lysoPAF acetyltransferase in leukocyte-rich plasma: use in PAF antagonist studies.. Lipids 26(12):997-1003 PMID: 1819756
- 7. Snyder F. 1995. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes.. Biochim Biophys Acta 1254(3):231-49 PMID: 7857964
- 8. West RR et al.. 1996. ZG-1494 alpha, a novel platelet-activating factor acetyltransferase inhibitor from Penicillium rubrum, isolation, structure elucidation andbiological activity.. J Antibiot (Tokyo) 49(10):967-73 PMID: 8968388
